HC Wainwright Has Lowered Expectations for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target reduced by equities research analysts at HC Wainwright from $54.00 to $52.00 in a report issued on Tuesday, Marketbeat.com reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 44.24% from the stock’s current price.

A number of other equities research analysts also recently weighed in on AGIO. The Goldman Sachs Group boosted their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research report on Wednesday, April 1st. Bank of America raised their target price on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Truist Financial upped their target price on Agios Pharmaceuticals from $36.00 to $41.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Wednesday, June 24th. Finally, JPMorgan Chase & Co. cut their price target on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a report on Thursday, June 11th. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Agios Pharmaceuticals has a consensus rating of “Hold” and an average price target of $42.78.

Agios Pharmaceuticals Price Performance

Shares of AGIO opened at $36.05 on Tuesday. The business’s fifty day moving average price is $33.58 and its 200 day moving average price is $30.56. Agios Pharmaceuticals has a 12-month low of $22.24 and a 12-month high of $46.00. The stock has a market capitalization of $2.14 billion, a PE ratio of -4.97 and a beta of 0.54.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, beating the consensus estimate of ($1.81) by $0.12. The firm had revenue of $20.75 million during the quarter, compared to analyst estimates of $13.30 million. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The business’s revenue was up 137.7% on a year-over-year basis. As a group, research analysts anticipate that Agios Pharmaceuticals will post -6.32 earnings per share for the current fiscal year.

Institutional Trading of Agios Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Handelsbanken Fonder AB boosted its position in Agios Pharmaceuticals by 35.2% during the 2nd quarter. Handelsbanken Fonder AB now owns 26,123 shares of the biopharmaceutical company’s stock worth $969,000 after acquiring an additional 6,800 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Agios Pharmaceuticals by 54.8% during the second quarter. Assenagon Asset Management S.A. now owns 103,955 shares of the biopharmaceutical company’s stock valued at $3,858,000 after purchasing an additional 36,802 shares during the period. Versant Capital Management Inc increased its holdings in shares of Agios Pharmaceuticals by 378.7% during the second quarter. Versant Capital Management Inc now owns 2,001 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 1,583 shares during the period. Seven Fleet Capital Management LP raised its stake in shares of Agios Pharmaceuticals by 560.2% during the first quarter. Seven Fleet Capital Management LP now owns 209,547 shares of the biopharmaceutical company’s stock valued at $7,089,000 after purchasing an additional 177,809 shares in the last quarter. Finally, California State Teachers Retirement System raised its stake in shares of Agios Pharmaceuticals by 28.8% during the first quarter. California State Teachers Retirement System now owns 68,564 shares of the biopharmaceutical company’s stock valued at $2,320,000 after purchasing an additional 15,325 shares in the last quarter.

More Agios Pharmaceuticals News

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Negative Sentiment: Agios scrapped the tebapivat sickle cell disease program after Phase 2 data failed to show a compelling benefit versus existing options, a setback that weakens a key pipeline opportunity. Article Title
• Negative Sentiment: Multiple reports highlighted the stock’s decline following the decision, with coverage emphasizing that the company is abandoning the sickle cell candidate after lackluster trial results. Article Title
• Negative Sentiment: Investor sentiment is also being dampened by the loss of a potential growth driver in sickle cell disease, even though Agios’ other PK activator, mitapivat, remains under FDA Priority Review with a PDUFA date of November 1, 2026. Article Title

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.